CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial
Official title: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma
Funded at March Biosciences INC · NIH-11370276 · Data updated 2026-11-12
A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | March Biosciences INC NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 1, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,124,607 |
| NIH project number | 5R44CA302357-02 |
| Project ID | NIH-11370276 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed or refractory T-cell lymphoma who express CD5 and meet specific safety criteria.
✕Less likely to help
Patients whose disease does not respond to MB-105 or who experience prohibitive toxicity may not benefit.
What this research studies
This study builds on earlier work showing CD5 CAR-T cells can target malignant T-cells while sparing normal ones. It uses an optimized manufacturing process to create more robust CAR-T cells and reduce fratricide in patients with T-cell cancers. The trial design involves multiple centers to evaluate safety and preliminary effectiveness in relapsed or refractory TCL patients treated with MB-105. If successful, it could pave the way for new options where few treatments exist. Participants will be monitored for responses and potential treatment-related side effects over time.
Why it matters
Potential benefit: If successful, patients could experience tumor reduction and longer survival with a therapy tailored to their T-cell lymphoma.
How similar studies have gone: Previous Phase 1 data showed manageable safety and some complete responses, suggesting potential for greater activity with improved manufacturing.
Where this research is happening
-
March Biosciences INC
Houston, United States Active
Researchers
- Principal investigator: Hein, Sarah Marie — March Biosciences INC
- Study coordinator: Hein, Sarah Marie
Related research
Other NIH-funded projects on the same topics.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
How a rare intestinal T‑cell lymphoma begins
This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.
-
Understanding how IL-15 affects T-cell lymphoma in the skin
This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.